http://www.newstin.co.uk/uk/MYRIAD_GENETICS Global Social News Platform Copyright © 2006 I2S a.s. Copyright © 2006 I2S a.s. http://www.newstin.co.uk/tag/uk/75745896 It's either the best of times or the worst of times. Even though the market averages have been getting beaten up, a few sectors -- like coal and oil & gas -- have surged. For early investors in companies such as Alpha... Thu, 28 Aug 2008 18:22:38 GMT http://www.newstin.co.uk/tag/uk/75745896 2008-08-28T18:22:38Z http://www.newstin.co.uk/tag/uk/75678781 Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has been deemed in compliance with the Nasdaq Hearings Panel’s decision dated August 6, 2008 and that accordingly, the... Thu, 28 Aug 2008 01:20:55 GMT http://www.newstin.co.uk/tag/uk/75678781 2008-08-28T01:20:55Z http://www.newstin.co.uk/tag/uk/75491159 I assume Sequenom (SQNM) is up nearly 8% as I write this on Friday's Investor Business Daily mention. The story highlighted the company along with Myriad Genetics (MYGN) which I also have looked at closely and strikes my... Mon, 25 Aug 2008 16:32:00 GMT http://www.newstin.co.uk/tag/uk/75491159 2008-08-25T16:32:00Z http://www.newstin.co.uk/tag/uk/75237050 Even though you can see some of my featured design work in my gallery and some of my earlier work from the U of U School of Business, the Junior League of Salt Lake City, and Myriad Genetics, Inc. on this older portfolio, I... Thu, 21 Aug 2008 14:49:29 GMT http://www.newstin.co.uk/tag/uk/75237050 2008-08-21T14:49:29Z http://www.newstin.co.uk/tag/uk/75190993 General Growth Properties (GGP) is the second largest shopping center owner, manager, and developer in the US. Currently, the company owns and manages a portfolio of more than 200 regional shopping malls in 44 states.[More...] Thu, 21 Aug 2008 13:32:00 GMT http://www.newstin.co.uk/tag/uk/75190993 2008-08-21T13:32:00Z http://www.newstin.co.uk/tag/uk/75147010 CHICAGO - Zacks Equity Research highlights Petroleum Development (Nasdaq: PETD) as the Bull of the Day and Ford Motor Company (NYSE: F) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Myriad... Thu, 21 Aug 2008 10:01:52 GMT http://www.newstin.co.uk/tag/uk/75147010 2008-08-21T10:01:52Z http://www.newstin.co.uk/tag/uk/75146427 Via Acquire Media NewsEdge) Aug. 21--Myriad Genetics Inc. is exploring splitting itself into two entities one to pursue its drug development activities and the other to handle its genetic-testing businesses. The company, which... Thu, 21 Aug 2008 05:23:35 GMT http://www.newstin.co.uk/tag/uk/75146427 2008-08-21T05:23:35Z http://www.newstin.co.uk/tag/uk/75065422 In the wake of a failed Phase III trial of Flurizan in Alzheimer's disease, Myriad Genetics Inc. is rethinking its business strategy, including the possibility of splitting up its molecular diagnostics and pharmaceutical... Wed, 20 Aug 2008 19:28:34 GMT http://www.newstin.co.uk/tag/uk/75065422 2008-08-20T19:28:34Z http://www.newstin.co.uk/tag/uk/75026483 Wednesday August 20, 2:59 pm ET By Grant Zeng, CFA The recent discontinuation of Myriad Genetics, Inc.'s (NasdaqGS: MYGN - News) lead candidate Flurizan, a treatment for Alzheimer's disease, concerns us about the company's... Wed, 20 Aug 2008 19:21:39 GMT http://www.newstin.co.uk/tag/uk/75026483 2008-08-20T19:21:39Z http://www.newstin.co.uk/tag/uk/74940082 SAN FRANCISCO, Aug. 20 /PRNewswire/ -- Emerging therapeutic strategies for Alzheimer's disease is the focus of the most recent edition of Neurotech Insights, the leading monthly industry newsletter covering drugs, devices and... Wed, 20 Aug 2008 12:45:00 GMT http://www.newstin.co.uk/tag/uk/74940082 2008-08-20T12:45:00Z